louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01906450: STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER HIGH SENSITIVE C-REACTIVE PROTEIN. RANDOMIZED CONTROLLED CLINICAL TRIAL.
Official title: STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER HIGH SENSITIVE C-REACTIVE PROTEIN. RANDOMIZED CONTROLLED CLINICAL TRIAL.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Periodontitis
Lead sponsor: Universidad del Valle, Colombia
Sponsor class: OTHER
First posted: 2013-07-24
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Human periodontitis is a group of highly prevalent oral inflammatory diseases and infections with relatively easy treatment and preventive features. The present study is aimed to determine if treating human individuals with chronic periodontitis, along with the use of antibiotics, reduces cardiovascular risk marker (HsPCR) and also intends to identify if severity of periodontitis could be associated with a raise of systemic inflammatory biomarkers on baseline.


Eligibility criteria: Inclusion Criteria:

* must be of legal age (≥ 18 years old)
* voluntary participation and signed information consent
* confirmed systemically healthy individual
* at least 15 teeth present in mouth

Exclusion Criteria

* pregnant women
* smokers
* antibiotic consumption 6 months before inclusion
* HIV positive or AIDS
* Allergic reactions to macrolides and specifically to azithromycin
* Periodontal treatment 6 months before inclusion

Primary outcomes:
measure: EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER HIGH SENSITIVE C-REACTIVE PROTEIN.
timeFrame: 3 months
Secondary outcomes:
measure: STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER LIPIDIC PROFILE
timeFrame: 3 months
measure: STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER GLYCEMIA LEVELS
timeFrame: 3 months
measure: STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER BLOOD BIOCHEMISTRY
timeFrame: 3 MONTHS
Other outcomes:
measure: STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER PERIODONTAL PARAMETERS
timeFrame: 3 months
Locations:
city: Cali
country: Colombia
facility: Universidad Del Valle
Study officials:
References:
Clinical trial NCT02695550: Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer
Official title: Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Non-small Cell Lung Cancer
Lead sponsor: Centaurus Biopharma Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2016-03-01
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase I study of the ALK/FAK/Pyk2 inhibitor CT-707 in patients with ALK-positive non-small cell lung cancer.

The purpose of the study is to determine the MTD/RP2D of CT-707 and evaluate whether CT-707 is safe and has beneficial effects in ALK-positive advanced non-small cell lung cancer.


Eligibility criteria: Inclusion Criteria:

Patients must be diagnosed with ALK-positive advanced NSCLC. The tumor must be ALK-positive as determined by ALK rearrangement in ≥15% of cells (as measured by FISH using the Vysis break-apart ALK probe) or by using the Ventana ALK IHC test. The analysis may be performed locally.

Eastern cooperative oncology group (ECOG) performance status ≤ 2. Measurable disease as per RECIST v1.1

Availability of tumor sample:

Exclusion Criteria:

Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or require increasing doses of steroids or local CNS-directed therapy to control their CNS disease Impaired cardiac function or any clinically significant cardiac disease Patients with abnormal laboratory values during screening and on day 1 of pre-dose Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CT-707 Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Incidence rate of dose limiting toxicities (DLTs) during the first cycle of treatment (Phase I)
timeFrame: 28 days
measure: Frequency of adverse events/serious adverse events
timeFrame: Up to 24 months
Secondary outcomes:
measure: Overall Response Rate (ORR) - Phase I
timeFrame: Up to 24 month
measure: Progression free survival (PFS) per RECIST v1.1 - Phase I
timeFrame: Up to 24 months
measure: Duration of response (DOR)
timeFrame: Up to 24 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Hospital of Chinese Academy of Medical Sciences
state: Beijing
Study officials:
affiliation: Cancer Hospital of Chines Academy of Medical Sciences
name: Yuankai Shi, Dr
role: PRINCIPAL_INVESTIGATOR
References:
citation: Liang C, Zhang N, Tan Q, Liu S, Luo R, Wang Y, Shi Y, Han X. CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK. Curr Cancer Drug Targets. 2019;19(8):655-665. doi: 10.2174/1568009618666181031152140.
Clinical trial NCT01868750: Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia
Official title: A Phase 2, Placebo-controlled, Randomized Study to Evaluate the Effect of Pre-operative Vitamin D Supplementation on Hypocalcemia Following Total or Near-total Thyroidectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Thyroid Nodules
Hypocalcemia
Lead sponsor: University of Virginia
Sponsor class: OTHER
First posted: 2013-06-04
Enrollment: 67
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: One of the major side effects of surgery to remove the thyroid gland is transient (lasting for a short time) low calcium levels in the blood, or "hypocalcemia." Low calcium levels can cause symptoms such as numbness around the mouth, tingling or cramping in the hands and feet, severe muscle spasms, inability to breathe, or heart rhythm (heart beat) abnormalities. Severe symptoms are life threatening, so it is important to start the management of these symptoms in the hospital. Treating low calcium levels sometimes require patients to spend a few extra days in the hospital.

The human body needs vitamin D to function and stay healthy. Vitamin D helps the body get the calcium needed to make strong bones and teeth. The purpose of this study is to determine if taking vitamin D before surgery to remove the thyroid gland affects whether or not you may have low calcium levels after your surgery and to test the hypothesis that those who are given the Vitamin D before surgery will have decreased hypocalcemia and a shortened hospital stay.


Eligibility criteria: Inclusion Criteria:

* Patient referred for thyroidectomy
* Agreement to use contraception prior to and during the study

Exclusion Criteria:

* Hypercalcemia (\>10.5mg/dL)
* Chronic kidney or parathyroid disease
* Cardiac or Central Nervous System disease
* Pregnant or breastfeeding women

Primary outcomes:
measure: Measure of Serum Calcium Levels
timeFrame: 2-5 days after surgery
Secondary outcomes:
measure: Evidence of Hypocalcemia
timeFrame: 2-5 days after surgery
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
Study officials:
affiliation: University of Virginia
name: David C Shonka, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01409850: Comparison Study of Two Splints Used for Treatment of Acute Temporomandibular Pain.
Official title: Pilot Clinical Trial on the Treatment Effectiveness of Two Splints for Acute Temporomandibular Pain.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Myofascial Pain
Lead sponsor: Heidelberg University
Sponsor class: OTHER
First posted: 2011-08-04
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The most commonly applied treatment against acute temporomandibular signs and symptoms is pharmacotherapy. The evidence on treatment efficacy of non-medication treatments (like splints) is very low. Two very commonly used splints are the Aqualizer® and the soft polyester splint. These are splints applied for a short period of time, until the treatment with a hard splint and/or physiotherapy begins. Aim of this study is to compare the clinical short-time efficacy of these two splints for the treatment of acute temporomandibular pain and compare it to a control group receiving no therapy for that short time.

The study hypothesis is that there is a difference in pain reduction between the three groups of patients (two intervention and one control group).


Eligibility criteria: Inclusion Criteria:

* Adult patients, non-chronic orofacial pain

Exclusion Criteria:

* Pregnancy, chronic orofacial pain, dental treatment need, dental pain, edentulous space larger than 5mm, more than three molars missing in the same quadrant, rheumatic disease, Injury/operation in maxillofacial area.

Primary outcomes:
measure: Pain
timeFrame: 2-3 weeks
Secondary outcomes:
measure: mouth opening
timeFrame: 2-3 weeks
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Department of Prosthodontics, University Clinic of Heidelberg
state: Baden-Württemberg
Study officials:
References:
Clinical trial NCT01151150: The Phenomenon of "Chronic Lyme"; an Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Lyme Borreliosis
Lead sponsor: Sorlandet Hospital HF
Sponsor class: OTHER_GOV
Collaborators: name: South-Eastern Norway Regional Health Authority
First posted: 2010-06-25
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients are eligible if they themselves or their physician suspected that they suffer from ongoing chronic Bb infection

Brief summary: The current study is set up to chart clinically and laboratory findings in Norwegian patients with symptoms attributed by themselves or their doctor to ongoing chronic Bb infection. Objectives is to assess laboratory findings in relation to established diagnostic criteria and to form a picture of the burden of symptoms and illness perception in this group of patients. The study is essentially exploratory, and is supposed to raise rather than to test hypotheses.


Eligibility criteria: Inclusion Criteria:

* Symptoms attributed by themselves or their doctor to ongoing chronic Bb infection

Exclusion Criteria:

* None

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kristiansand
country: Norway
facility: Sølandet Hospital HF
Study officials:
References:
Clinical trial NCT02759250: A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
Official title: A Pilot, Phase Ib Feasibility Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cancer
Lead sponsor: argenx
Sponsor class: INDUSTRY
First posted: 2016-05-03
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).


Eligibility criteria: Inclusion criteria:

* Age ≥18 years.
* Written informed consent prior to any study-related procedure
* Willing and able to comply with protocol-specified procedures and scheduled evaluations
* Pathological diagnosis of nasopharyngeal carcinoma (NPC)
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1or 2
* Absolute neutrophil count (ANC) \> 0.5 x 109/L
* Haemoglobin \> 80 g/L
* Platelet count ≥ 50 x 109/L
* Total bilirubin ≤ 2 x the upper limit of normal (ULN)
* Alanine transaminase (ALT) ≤ 5 x ULN
* Serum creatinine ≤ 2 x ULN

Exclusion criteria:

* History or clinical evidence of neoplastic central nervous system (CNS) involvement. Note: Irradiated brain metastases that have been stable for \> 1 month and do not require systemic glucocorticoid administration are allowed
* Major surgery within 4 weeks of ARGX-110 first dose administration
* Unresolved grade 3 or 4 toxicity from prior therapy (except mucositis from local radiation therapy).
* Active, untreated viral, bacterial, or systemic fungal infection
* Childbearing potential unless using an adequate measure of contraception
* Pregnancy or lactation. History of hypersensitivity to recombinant proteins
* Any clinical finding, including psychiatric and behavioural problems, which, in the opinion of the Investigator, precludes the patient from safely participating in the study

Primary outcomes:
measure: Incidence and grading of AEs
timeFrame: measured at screening, Day 1, Day 8, Day 15, Day 42, thereafter every 42 days until Day 378
Secondary outcomes:
measure: Pharmacokinetic profile of ARGX110 by Cmax
timeFrame: measured at Day 1 pre and post dose, Day 8, Day 15, Day 42 pre and post dose and thereafter every 42 days until Day 378
measure: Pharmacokinetic profile of ARGX110 by AUC
timeFrame: measured at Day 1 pre and post dose, Day 8, Day 15, Day 42 pre and post dose and thereafter every 42 days until Day 378
measure: Biomarkers CD70 immunohistochemistry (IHC)
timeFrame: measured at Screening, Day 42, and thereafter every 42 days until day Day 378
Other outcomes:
Locations:
city: Gent
country: Belgium
facility: UZG - Universitair Ziekenhuis Gent
Study officials:
affiliation: UZG - Universitair Ziekenhuis Gent
name: Sylvie Rottey, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06256250: Assessment of Post-operative Pain After Different Instrumentation Techniques in Pulpectomy Treatment of Primary Molars
Official title: The Effect of Different Instrumentation Techniques on the Post-Operative Pain in Pulpectomy Treatment of Primary Molars: A Blind Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Pulp Necroses
Keywords: pulpectomy, XP endo shaper, post operative pain
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2024-02-13
Enrollment: 75
Sex: ALL
Minimum age (years): 4
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to compare the post operative pain after using three different instrumentation techniques in pulpectomy treatment of pediatric participant. The main question it aims to answer:

If different instrumentation techniques will affect the post operative pain in pulpectomy treatment of primary molars ? Participants will evaluate the pain using Modified Wong baker pain rating scale.

Researchers will compare \[ the adaptive XP endo shaper, Fanta AF baby files, and hand K files\] to see if they will affect the post operative pain.


Eligibility criteria: Inclusion Criteria:

* Cooperative children free from systemic diseases.
* Teeth with sufficient coronal tooth structure.
* Teeth with necrotic pulp.
* Teeth should have 2/3 of the remaining roots.

Exclusion Criteria:

* Children taking medications up to six hours before the treatment.
* Children with multiple teeth that required pulpectomy will not be included to eliminate the possibility of pain referral.
* Excessive tooth mobility.
* Teeth with perforated pulpal floor.
* Teeth with external or internal root resorption.

Primary outcomes:
measure: Assessment of post-operative pain after pulpectomy treatment in primary teeth
timeFrame: one week
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Amal Taha Taha Elakkad
Study officials:
References:
Clinical trial NCT03402750: Heart Failure Medication Adherence
Official title: Heart Failure Medication Adherence Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure
Keywords: Adherence, Medication, Prescription
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Beta Tau Chapter of Sigma Theta Tau International
First posted: 2018-01-18
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The objective of this investigation is to pilot test a medication in-hand intervention (Meds to Beds) compared to standard care for patients with heart failure (ICD-50\[all numbers\]). The study will evaluate if the intervention improves adherence and physical health, and reduces hospital re-admissions. The study will provide evidence for the feasibility and acceptability of the medication-in-hand intervention.


Eligibility criteria: Inclusion Criteria:

* Admission diagnosis of heart failure ICD-50, including I50.1, I50.2, I50.20, I50.21, I50.22, I50.23, I50.3, I50.30, I50.31, I50.32, I50.33, I50.4, I50.40, I50.41, I50.42, I50.43, I50.8, I50.81, I50.810, I50.811, I50.812, I50.813, I50.814, I50.82, I50.83, I50.84, I50.89, I50.9, or any combination thereof
* Age 18 or older
* New York Heart Association Heart Failure Class II or Class III, with ejection fraction below 45%
* Cognitively intact, without significant psychological impairment affecting medication adherence such as dementia noted in patient record.

Exclusion Criteria:

* Medical conditions, such as active cancer or pregnancy, expected to alter heart failure medication management
* Discharged to nursing homes or hospice care, where patient may not responsible for their own adherence
* High risk of loss to follow-up, e.g., leaving the hospital against medical advice, prisoners, living in a homeless shelter, or unable to provide a phone number
* No plan to fill medications at the Jackson Memorial Hospital pharmacy

Primary outcomes:
measure: Adherence to Medication
timeFrame: Day 30
measure: Pharmacy Refill Adherence to Medication
timeFrame: Day 30
Secondary outcomes:
measure: Physical Health as Assessed by the Patient-Reported Outcome Measurement Information System (PROMIS) Questionnaire
timeFrame: Baseline and Day 30
measure: Number of Participants That Received Their Medications Prior to Discharge.
timeFrame: Day 0
measure: Intervention Acceptance
timeFrame: Day 30
Other outcomes:
Locations:
city: Miami
country: United States
facility: Jackson Memorial Hospital
state: Florida
Study officials:
affiliation: University of Miami
name: Brian E McCabe, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01953250: Functional Outcome in Patients That Underwent Laparoscopic Sigmoid and/or Rectum Resection
Official title: To Assess the Functional Outcome in Patients That Underwent Laparoscopic Sigmoid and/or Rectum Resection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometriosis
Keywords: Deep infiltrating endometriosis
Laparoscopic sigmoid resection
laparoscopic rectum resection
Colorectal surgery
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2013-09-30
Enrollment: 143
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 272 patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis

Brief summary: Questionnaire To assess the functional outcome in patients that underwent laparoscopic sigmoid and/or rectum resection.

Detailed description: A questionnaire will be sent to every patient by mail. The questionnaire that will be used is the COREFO questionnaire (ColoRectal Functional Outcome).

Depending on the amount of responses, we will try to make connections between peri-operative data and functional outcome after considerable period of follow-up. Peri-operative factors include grade of endometriosis, surgical technique and post-operative complications.

Eligibility criteria: Inclusion Criteria:

* Patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis

Exclusion Criteria:

-

Primary outcomes:
measure: ColoRectal Functional Outcome
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: University Clinics Gasthuisberg
state: Flemish Brabant
Study officials:
affiliation: University Clinics Gasthuisberg Department of Abdominal Surgery
name: André JL D'Hoore, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03285750: Expression of G-protein Coupled Receptor 120 Receptor in Adipose Tissue of German Diabetes Center Cohort Subjects
Official title: Expression of GPR120 Receptor in Adipose Tissue of Type 2 Diabetic Subjects
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type 2 Diabetes
Keywords: GPR120
Adipose tissue
Type 2 diabetes
Lead sponsor: German Diabetes Center
Sponsor class: OTHER
First posted: 2017-09-18
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with recently diagnosed type 2 diabetes (up to one year from diagnosis) and age- and weight-matched normoglycemic controls

Brief summary: G-protein coupled receptor 120 (GPR120) is a G-protein-coupled receptor whose endogenous ligands have been identified as long-chain fatty acids. Recently, it has been shown that GPR120 expression in human adipose tissue is higher in obese than in lean individuals. Interestingly, a GPR120 deficient mouse model presents an unfavorable phenotype when fed a high-fat diet with obesity, glucose intolerance and fatty liver, characteristics also found in type 2 diabetes (T2D).

Moreover, in obese subjects, a single nucleotide polymorphism (R270H) has been identified that inhibits GPR120 signaling activity.

The investigators now want to investigate if GPR120 expression in adipose tissue may be altered in patients with T2D compared to non-diabetic subjects and might contribute to diabetes-associated metabolic changes. Additionally, the investigators want to assess the frequency of the R270H mutant in T2D.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes mellitus / normoglycemia
* BMI \< 27,5 or \> 30 kg/m2
* Age 20 - 69 years

Exclusion Criteria:

* severe chronic diseases
* anemia
* medication altering fatty acid metabolism

Primary outcomes:
measure: GPR120 expression in adipose tissue
timeFrame: Expression measured at baseline (day 1)
Secondary outcomes:
Other outcomes:
Locations:
city: Duesseldorf
country: Germany
facility: German Diabetes Center
state: Nordrhein-Westfalen
Study officials:
affiliation: German Diabetes Center
name: Michael Roden, Prof., MD
role: PRINCIPAL_INVESTIGATOR
References: